Workshop highlights include:
- Discussing the growing need for novel ADC payloads in the face of ADC patient resistance mechanisms
- Weighing up the pros and cons of novel cytotoxic, catalytic, oligonucleotide, and immune-stimulating payload safety and efficacy
- Assessing MoA characterization of ADC payloads beyond classical cytotoxic agents